Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) is anticipated to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. On average, analysts expect Lexeo Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lexeo Therapeutics Trading Up 1.6%

Shares of LXEO stock traded up $0.09 during trading hours on Monday, hitting $5.86. 38,831 shares of the company were exchanged, compared to its average volume of 977,768. The business has a 50 day moving average of $6.29 and a two-hundred day moving average of $7.89. Lexeo Therapeutics has a 52 week low of $2.43 and a 52 week high of $10.99. The company has a market capitalization of $460.13 million, a PE ratio of -2.67 and a beta of 1.52.

Analyst Ratings Changes

Several brokerages recently commented on LXEO. HC Wainwright reduced their target price on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Chardan Capital restated a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. Finally, Wall Street Zen cut shares of Lexeo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.88.

Insider Buying and Selling

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the sale, the chief executive officer owned 340,106 shares in the company, valued at $1,935,203.14. This trade represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,189 shares of company stock valued at $397,156 in the last ninety days. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its position in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after purchasing an additional 2,148 shares during the period. Cerity Partners LLC bought a new position in shares of Lexeo Therapeutics in the second quarter valued at about $50,000. Russell Investments Group Ltd. raised its position in shares of Lexeo Therapeutics by 160.2% in the fourth quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock valued at $58,000 after purchasing an additional 3,615 shares during the period. Acadian Asset Management LLC bought a new position in shares of Lexeo Therapeutics in the first quarter valued at about $85,000. Finally, Scientech Research LLC bought a new position in shares of Lexeo Therapeutics in the third quarter valued at about $90,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.